| MeSH term | MeSH ID | Detail |
|---|---|---|
| Lentigo | D007911 | 1 associated lipids |
| Cardiomyopathy, Restrictive | D002313 | 1 associated lipids |
| Digestive System Fistula | D016154 | 1 associated lipids |
| Uveitis, Intermediate | D015867 | 3 associated lipids |
| Miller Fisher Syndrome | D019846 | 1 associated lipids |
| Colitis, Collagenous | D046729 | 1 associated lipids |
| Tumor Lysis Syndrome | D015275 | 2 associated lipids |
| Autoimmune Diseases of the Nervous System | D020274 | 1 associated lipids |
| Candidiasis, Vulvovaginal | D002181 | 8 associated lipids |
| Ecthyma, Contagious | D004474 | 1 associated lipids |
tacrolimus
Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
Cross Reference
Introduction
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with tacrolimus?
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with tacrolimus
PubChem Associated disorders and diseases
What pathways are associated with tacrolimus
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with tacrolimus?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with tacrolimus?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with tacrolimus?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with tacrolimus?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with tacrolimus?
There are no associated biomedical information in the current reference collection.
NCBI Entrez Crosslinks
All references with tacrolimus
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Gaynor JJ and Ciancio G | The Importance of Using Serially Measured Tacrolimus Clearance Values, Especially During the Early Posttransplantation Period. | 2018 | Transplantation | pmid:29271869 |
| Shivaswamy V et al. | Tacrolimus and sirolimus induce reproductive abnormalities in female rats. | 2011 | Transplantation | pmid:21508897 |
| McCune TR et al. | Effects of tacrolimus on hyperlipidemia after successful renal transplantation: a Southeastern Organ Procurement Foundation multicenter clinical study. | 1998 | Transplantation | pmid:9448150 |
| Selzner N et al. | Antiviral treatment of recurrent hepatitis C after liver transplantation: predictors of response and long-term outcome. | 2009 | Transplantation | pmid:19935376 |
| Rush DN et al. | Factors associated with progression of interstitial fibrosis in renal transplant patients receiving tacrolimus and mycophenolate mofetil. | 2009 | Transplantation | pmid:19935461 |
| Neylan JF | Racial differences in renal transplantation after immunosuppression with tacrolimus versus cyclosporine. FK506 Kidney Transplant Study Group. | 1998 | Transplantation | pmid:9500626 |
| Kim YI et al. | Stimulation of liver regeneration by pretreatment with azathioprine as well as cyclosporine and FK506. | 1992 | Transplantation | pmid:1373539 |
| D'Antiga L et al. | Late cellular rejection in paediatric liver transplantation: aetiology and outcome. | 2002 | Transplantation | pmid:11792983 |
| Gupta A et al. | Elevated myeloid: plasmacytoid dendritic cell ratio associates with late, but not early, liver rejection in children induced with rabbit anti-human thymocyte globulin. | 2009 | Transplantation | pmid:19696644 |
| Gerlach UA et al. | Intragraft and Systemic Immune Parameters Discriminating Between Rejection and Long-Term Graft Function in a Preclinical Model of Intestinal Transplantation. | 2017 | Transplantation | pmid:27607529 |
| Kessler M et al. | A renal allograft recipient with late recurrence of focal and segmental glomerulosclerosis after switching from cyclosporine to tacrolimus. | 1999 | Transplantation | pmid:10071045 |
| Rostaing L et al. | Corticosteroid-free immunosuppression with tacrolimus, mycophenolate mofetil, and daclizumab induction in renal transplantation. | 2005 | Transplantation | pmid:15818323 |
| Mueller AR et al. | Neurotoxicity after orthotopic liver transplantation. A comparison between cyclosporine and FK506. | 1994 | Transplantation | pmid:7518974 |
| Takaya S et al. | Liver transplantation in positive cytotoxic crossmatch cases using FK506, high-dose steroids, and prostaglandin E1. | 1992 | Transplantation | pmid:1279851 |
| Wasik M et al. | Effect of FK506 versus cyclosporine on human natural and antibody-dependent cytotoxicity reactions in vitro. | 1991 | Transplantation | pmid:1702910 |
| di Francesco F et al. | One year follow-up of steroid-free immunosuppression plus everolimus in isolated pancreas transplantation. | 2008 | Transplantation | pmid:18946356 |
| Mahé E et al. | Drug-induced hypersensitivity syndrome associated with primary Epstein-Barr virus and human herpesvirus 6 infections in a child intestinal transplant recipient. | 2004 | Transplantation | pmid:14966435 |
| Paramesh AS et al. | Thrombotic microangiopathy associated with combined sirolimus and tacrolimus immunosuppression after intestinal transplantation. | 2004 | Transplantation | pmid:14724447 |
| Jain AB et al. | Comparative incidence of de novo nonlymphoid malignancies after liver transplantation under tacrolimus using surveillance epidemiologic end result data. | 1998 | Transplantation | pmid:9825817 |
| Yoshimura N et al. | Effect of a new immunosuppressive agent, FK506, on human lymphocyte responses in vitro. I. Inhibition of expression of alloantigen-activated suppressor cells, as well as induction of alloreactivity. | 1989 | Transplantation | pmid:2465592 |
| Gruessner RW and Sharp HL | Living-related intestinal transplantation: first report of a standardized surgical technique. | 1997 | Transplantation | pmid:9415566 |
| Yoshimura N et al. | Effect of a new immunosuppressive agent, FK506, on human lymphocyte responses in vitro. II. Inhibition of the production of IL-2 and gamma-IFN, but not B cell-stimulating factor 2. | 1989 | Transplantation | pmid:2465593 |
| Gujadhur A et al. | CMV sinusitis in a HIV-negative renal transplant recipient. | 2014 | Transplantation | pmid:24827770 |
| Takatsuki M et al. | Weaning of immunosuppression in living donor liver transplant recipients. | 2001 | Transplantation | pmid:11502975 |
| Riegersperger M et al. | Effect of conversion from ciclosporin to tacrolimus on endothelial progenitor cells in stable long-term kidney transplant recipients. | 2013 | Transplantation | pmid:23594858 |
| Poncelet AJ et al. | Inhibition of humoral response to allogeneic porcine mesenchymal stem cell with 12 days of tacrolimus. | 2008 | Transplantation | pmid:19077894 |
| Uchida N et al. | Mycophenolate and tacrolimus for graft-versus-host disease prophylaxis for elderly after cord blood transplantation: a matched pair comparison with tacrolimus alone. | 2011 | Transplantation | pmid:21677598 |
| Josephson MA et al. | Treatment of renal allograft polyoma BK virus infection with leflunomide. | 2006 | Transplantation | pmid:16534472 |
| Wu MJ et al. | Lower variability of tacrolimus trough concentration after conversion from prograf to advagraf in stable kidney transplant recipients. | 2011 | Transplantation | pmid:21912349 |
| Stempfle HU et al. | The role of tacrolimus (FK506)-based immunosuppression on bone mineral density and bone turnover after cardiac transplantation: a prospective, longitudinal, randomized, double-blind trial with calcitriol. | 2002 | Transplantation | pmid:11889427 |
| van Maarseveen EM et al. | Pretransplantation pharmacokinetic curves of tacrolimus in HIV-infected patients on ritonavir-containing cART: a pilot study. | 2013 | Transplantation | pmid:23250333 |
| Charpentier B et al. | A three-arm study comparing immediate tacrolimus therapy with antithymocyte globulin induction therapy followed by tacrolimus or cyclosporine A in adult renal transplant recipients. | 2003 | Transplantation | pmid:12660513 |
| Kim SJ et al. | A comparison of the effects of C2-cyclosporine and C0-tacrolimus on renal function and cardiovascular risk factors in kidney transplant recipients. | 2006 | Transplantation | pmid:17038908 |
| Deuse T et al. | Significant reduction of acute cardiac allograft rejection by selective janus kinase-1/3 inhibition using R507 and R545. | 2012 | Transplantation | pmid:22971540 |
| Jain A et al. | One thousand consecutive primary liver transplants under tacrolimus immunosuppression: a 17- to 20-year longitudinal follow-up. | 2011 | Transplantation | pmid:21378604 |
| Gruessner RW et al. | Portal donor-specific blood transfusion and mycophenolate mofetil allow steroid avoidance and tacrolimus dose reduction with sustained levels of chimerism in a pig model of intestinal transplantation. | 2004 | Transplantation | pmid:15239611 |
| Bendahan J et al. | The effect of administration of FK506 on delayed regeneration in flushed partially hepatectomized livers. | 1994 | Transplantation | pmid:7511255 |
| Margreiter R et al. | A double-hand transplant can be worth the effort! | 2002 | Transplantation | pmid:12134104 |
| Wiesner RH | A long-term comparison of tacrolimus (FK506) versus cyclosporine in liver transplantation: a report of the United States FK506 Study Group. | 1998 | Transplantation | pmid:9734494 |
| Report from the 4th International Workshop on Clinical Pharmacology of HIV Therapy. Drug levels in PHAs who receive liver transplants. | 2003 Apr-May | TreatmentUpdate | pmid:17216847 | |
| Kunz J and Hall MN | Cyclosporin A, FK506 and rapamycin: more than just immunosuppression. | 1993 | Trends Biochem. Sci. | pmid:7694398 |
| Cardenas ME et al. | Signal-transduction cascades as targets for therapeutic intervention by natural products. | 1998 | Trends Biotechnol. | pmid:9807840 |
| Snyder SH et al. | Neural actions of immunophilin ligands. | 1998 | Trends Pharmacol. Sci. | pmid:9509898 |
| Liu J | FK506 and ciclosporin: molecular probes for studying intracellular signal transduction. | 1993 | Trends Pharmacol. Sci. | pmid:7692652 |
| Chang JY et al. | FK506 and rapamycin: novel pharmacological probes of the immune response. | 1991 | Trends Pharmacol. Sci. | pmid:1710854 |
| Sommerer C et al. | Design and rationale of the ATHENA study--A 12-month, multicentre, prospective study evaluating the outcomes of a de novo everolimus-based regimen in combination with reduced cyclosporine or tacrolimus versus a standard regimen in kidney transplant patients: study protocol for a randomised controlled trial. | 2016 | Trials | pmid:26888217 |
| Nashan B et al. | Evaluating the efficacy, safety and evolution of renal function with early initiation of everolimus-facilitated tacrolimus reduction in de novo liver transplant recipients: Study protocol for a randomized controlled trial. | 2015 | Trials | pmid:25873064 |
| Bajetta E et al. | Merkel cell carcinoma after liver transplantation: a case report. | 2007 May-Jun | Tumori | pmid:17679476 |
| Vennarecci G et al. | [Acute liver toxicity of antiretroviral therapy (HAART) after liver transplantation in a patient with HIV-HCV coinfection and associated hepatocarcinoma (HCC)]. | 2003 Jul-Aug | Tumori | pmid:12903579 |
| Tümgör G et al. | A case of uneventful ABO-incompatible liver transplantation from a deceased donor managed with routine immunosuppressive treatment. | 2014 | Turk J Gastroenterol | pmid:25599790 |